NCT04672005View on ClinicalTrials.gov

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

June 1, 2025

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

Folfirinox alternating with Gemcitabine-nab-Paclitaxel

modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel

Trial Locations (7)

08690

RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton

07302

RWJBarnabas Health - Jersey City Medical Center, Jersey City, Jersey City

07039

RWJBarnabas Health - Saint Barnabas Medical Center, Livingston, Livingston

07740

Monmouth Medical Center, Long Branch

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

07112

RWJBarnabas Health - Newark Beth Israel Medical Center, Newark

08873

RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset, Somerset

All Listed Sponsors
lead

Lyudmyla Berim

OTHER